Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027829 | 1.00 | RIPK1 (0.38) | RIPK1LMNASMN1; SMN2P2RX3DRD2 | |
| SCHEMBL3032270 | 0.92 | LMNA (0.39) | RIPK1LMNASMN1; SMN2P2RX3DRD2 | |
| SCHEMBL3032265 | 0.92 | LMNA (0.39) | RIPK1LMNASMN1; SMN2P2RX3DRD2 | |
| Hydrochloric Acid SCHEMBL3021424 | 0.91 | LMNA (0.38) | RIPK1LMNASMN1; SMN2P2RX3KDM4E | |
| SCHEMBL3025931 | 0.87 | GRIN1 (0.32) | LMNAKDM4E | |
| SCHEMBL3025929 | 0.87 | GRIN1 (0.32) | LMNAKDM4E | |
| SCHEMBL3030992 | 0.82 | GRIN1 (0.31) | LMNAKDM4E | |
| SCHEMBL3030990 | 0.82 | GRIN1 (0.31) | LMNAKDM4E | |
| SCHEMBL3027938 | 0.76 | GRIN1 (0.33) | LMNAKDM4EHPGDRAB9A | |
| Hydrochloric Acid SCHEMBL3032341 | 0.76 | GRIN1 (0.33) | LMNAKDM4EHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212309-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| US-8440701-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-14 | — | — | US | disclosed |
| US-20100216846-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-26 | — | — | US | disclosed |
| EP-2212309-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050186-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216846-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNB1 | RIPK1 3273/4885LMNA 4483/4885SMN1; SMN2 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.